CORONA Remedies Limited
CORONA Remedies Limited operates in Pharmaceuticals, part of the Healthcare sector. It booked ₹441 cr of revenue in its latest quarter (Q2 FY27) and kept 13.7% of sales as profit.
“is to be among the most appropriate balance of skills and experience.”
Healthier than 64% of companies in Healthcare, on the 5 of 6 measures we could read for it. Each measure is ranked against the 118–153 companies that reported it.
Measures financial condition, not whether to buy. Learn what this score means · How this is calculated
- RSI (14)
- 67
At close. Not part of the score.
How much profit it earns on the money it employs
How much it owes, and whether earnings cover the interest
Whether reported profit actually arrives as cash
What today's price implies, against our models or its peers
How much of the promoters' stake is pledged, and how much they hold · highest in its sector on what we could measure
Not measurable for this company: growth & consistency. Those pillars are left out of the score rather than counted as zero.
What if I invest in CORONA?
Set a growth rate and see what a monthly SIP would add up to. Your assumption, our arithmetic.
The slider starts at 5%, taken from a generic assumption, not this company's history. That is history, not a forecast — this is your assumption, and the figure above is arithmetic on it. Returns are not steady year to year, and a real holding would not grow in a straight line. We do not publish price targets or predict returns.
P/E, ROE, ROCE and margins are annualised from the latest quarter; per-share and balance-sheet ratios use the most recent balance sheet on file · prices as of 2026-11-04.
An educational model from the company's own filings, every assumption shown — not investment advice or a price target. Prices can stay above or below any model for years.
| Revenue from Operations | ₹441 cr |
| Other Income | ₹2 cr |
| Total Income | ₹444 cr |
| Cost of Materials | ₹35 cr |
| Purchases of Stock-in-Trade | ₹68 cr |
| Inventory Change (±) | ₹-23 cr |
| Employee Benefit Expense | ₹124 cr |
| Finance Costs | ₹3 cr |
| Depreciation & Amortisation | ₹15 cr |
| Other Expenses | ₹140 cr |
| Total Expenses | ₹363 cr |
| Profit before Tax | ₹81 cr |
| Tax Expense | ₹20 cr |
| Share of JV / Associates | ₹13 L |
| Net Profit | ₹60 cr |
| Net margin on total income | 13.6% |
| Metric | Q4 FY26 | Q1 FY27 | Q2 FY27 |
|---|---|---|---|
| Revenue | 353 cr | 422 cr | 441 cr |
| Total income | 357 cr | 426 cr | 444 cr |
| Expenses | 303 cr | 345 cr | 363 cr |
| Profit before tax | 55 cr | 80 cr | 81 cr |
| Tax | 9 cr | 20 cr | 20 cr |
| Net profit (owners' share) | 45 cr | 60 cr | 60 cr |
| Net margin (owners' share, on revenue) | 12.8% | 14.2% | 13.7% |
| EPS (₹) | 7.41 | 9.83 | 9.86 |
| Company | Price | Market cap | P/E | ROE | Net margin | 1-yr return |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹1,770 | ₹4.25 L cr | 53.3 | 8.9% | 12.3% | — |
| Divi's Laboratories Limited | ₹10,064 | ₹2.67 L cr | 74.1 | 21.5% | 29.3% | — |
| Torrent Pharmaceuticals Limited | ₹4,650 | ₹1.77 L cr | 82.7 | 11.6% | 10.7% | — |
| Laurus Labs Limited | ₹2,323 | ₹1.26 L cr | 71.1 | 29.1% | 20.0% | — |
| Zydus Lifesciences Limited | ₹1,241 | ₹1.24 L cr | 33.2 | 13.9% | 11.7% | — |
| Dr. Reddy's Laboratories Limited | ₹1,368 | ₹1.14 L cr | 30.8 | 9.5% | 10.6% | — |
| Cipla Limited | ₹1,397 | ₹1.13 L cr | 32.2 | 9.9% | 11.9% | — |
| Mankind Pharma Limited | ₹2,475 | ₹1.02 L cr | 35.9 | 16.2% | 16.4% | — |
| Aurobindo Pharma Limited | ₹1,695 | ₹97,502 cr | 23.7 | 10.9% | 11.3% | — |
| Action | Detail | Ex-date |
|---|---|---|
| Dividend | ₹10 / share | 19 Jun 2026 |
Most Indian companies are controlled by a family or group — the promoters. The exchange requires them to be listed by name, including members who own no shares at all, and requires the company to disclose any business it does with them.
The company also transacted with 13 other related parties — subsidiaries, joint ventures, directors and others — that we could not match by name to the promoter list above. Some may still be connected to the family; we only count the ones the filings let us match with certainty.
Names and holdings from the company’s shareholding pattern filed with the exchange; transactions from the related-party note in its annual report. Every figure is as filed — these are legal, disclosed dealings, and what to make of them is your call.